Detalles de la búsqueda
1.
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet;
400(10369): 2210-2220, 2022 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528376
2.
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
N Engl J Med;
383(2): 109-119, 2020 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32640130
3.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Mult Scler;
28(14): 2263-2273, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131595
4.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
J Neurol Neurosurg Psychiatry;
91(6): 660-668, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234967
5.
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
Mult Scler;
24(11): 1469-1484, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28799444
6.
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
J Infect Dis;
206(7): 1002-11, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22896665
7.
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.
J Lipid Res;
52(2): 361-73, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21068008
8.
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
J Clin Pharmacol;
61(3): 339-348, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949472
9.
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
CNS Drugs;
33(1): 61-79, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30535670
10.
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology;
93(15): e1452-e1462, 2019 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515290
11.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Lancet Neurol;
18(9): 845-856, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31285147
12.
Loss of elastic fibers causes skin wrinkles in sun-damaged human skin.
J Dermatol Sci;
50(2): 99-107, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18201872
13.
Biflavonoids isolated from Selaginella tamariscina regulate the expression of matrix metalloproteinase in human skin fibroblasts.
Bioorg Med Chem;
16(2): 732-8, 2008 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18029185
14.
Simultaneous determination of two Amadori compounds in Korean red ginseng (Panax ginseng) extracts and rat plasma by high-performance anion-exchange chromatography with pulsed amperometric detection.
J Chromatogr B Analyt Technol Biomed Life Sci;
865(1-2): 159-66, 2008 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18329967
15.
Suitability of macrophage inflammatory protein-1beta production by THP-1 cells in differentiating skin sensitizers from irritant chemicals.
Contact Dermatitis;
58(4): 193-8, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18353026
16.
Statistically designed enzymatic hydrolysis for optimized production of icariside II as a novel melanogenesis inhibitor.
J Microbiol Biotechnol;
18(1): 110-7, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18239426
17.
Simultaneous determination of heavy metals in cosmetic products.
J Cosmet Sci;
59(5): 441-8, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18841308
18.
Determination and validation of six sunscreen agents in suncare products by UPLC and HPLC.
J Cosmet Sci;
59(6): 469-80, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19156330
19.
Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sensitive liposomes into HM3KO melanoma cells.
J Cosmet Sci;
59(2): 139-50, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18408871
20.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Lancet Neurol;
17(5): 405-415, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545067